Investors Overview
A 200M market, still structured with 1970s workflows.
Microbiological testing remains one of the last largely non-digitized sectors in healthcare. With its AI, BioeurekaTM is changing the game, and the opportunity window is now open.
$92B
Global market by 2033
8.5%
Compound annual growth rate (CAGR)
4B+
Microbiological tests per year
$57
Average cost per test
Market segments
Three key industries.
All segments are urgent.
All are currently underserverd.
Food safety, clinical diagnostics, and environmental testing are facing increasing regulatory pressure to produce faster and more reliable results, while the market still lacks a fully adapted AI solution.
Food safety testing
$49B
Clinical diagnostics
$31B
Environmental testing
$12B
Competitive advantage
A truly unique innovation on the market.
| Approach | Cost | Turnaround Time | AI Guidance |
|---|---|---|---|
| Reference Lab | $43-72 | 2-5 days | No |
| Manual In-house Method | $15-25 | 1-2 days | No |
| BioeurekaTM | $9-15 | ½-1 day | Yes |
High return potential
Multiple exit scenarios already identified
Proprietary technology with strong barriers to entry
Proprietary AI models trained on millions of pathogen and microorganism image data points,
creating a cumulative data advantage that is difficult to replicate.
Recurring SaaS revenue driven by the AI platform.
Subscriptions are directly integrated into company workflows, enabling continuous and scalable adoption.
Integrated ecosystem of software and consumables,
fostering strong customer retention and recurring usage.
Favorable regulatory environment.
Strengthening food safety standards and the growing challenges related to antimicrobial resistance are accelerating global demand for testing solutions.
Strategic Acquisition
Positioned as a strong M&A target for global diagnostics leaders.
IPO Track
Scalable SaaS + consumables model aligned with high-growth MedTech and diagnostics platforms
Licensing
Flexible licensing or white-label model for regional labs and diagnostic networks, enabling rapid and scalable adoption.
Pharma Partnerships
Growing demand for AMR research enables enterprise data partnerships and licensing opportunities
